EX-99.3 5 factsheet.htm WORD VERSION OF FACT SHEET
 
PAGE 1
Investor Fact Sheet
Ticker Symbol: NASDAQ: CEMI
www.chembio.com

Business Summary & Investment Highlights
Chembio Diagnostics, Inc., (Chembio), through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures licenses and markets point-of-care testing (POCT) products.  Chembio has created and patented, in 2007, a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious disease testing market and other growing markets. Products developed and under development, both OEM and branded, are creating new revenue streams that are anticipated to add to Chembio's core business of rapid tests.
·
Strategy is to create core business of public health products to be complemented by OEM and selected out-licensing opportunities.
·
Robust pipeline of POCT products for infectious diseases based on Chembio's patented DPP® technology.
·
Products developed on DPP® platform include oral fluid HIV test CLIA waived by the  FDA in October 2014.   Several other products and collaborations in pipeline.
·
Commercial Activities in North America, South America, Europe, Africa and Asia Ongoing to Address Growing Global Market for POCTs
Selected Financial Information
Stock Information  as of 10/31/14
Ticker Symbol: NASDAQ: CEMI
Price 10/31/2014:   $4.28
52 Week High:     $5.20
52 Week Low:   $2.83
Outstanding Shares (MM): 9.61
Market Capitalization (MM): $41.14
Fully Diluted (FD) Shares (MM): 10.28
Management Holding-FD (MM):0.97
Average Daily Vol. (3 Mos):  94,000

Beneficial Holders Beneficial Shares Owned (000)s

Wellington Management Company, LLP: 958 
Lawrence Siebert: 550

 
See Graphics
  
   
 
 
 
 
 
Balance Sheet Data ($000s)
  
Sept. '14
    
Dec'13
  
Cash
  
$
3,673
    
$
9,650
  
Accts. Receivable
    
8,316
      
4,592
  
Inventories
    
3,975
      
3,189
  
Total Current Assets
    
16,999
      
18,531
  
Net Fixed Assets
    
2,119
      
1,978
  
Total Assets
    
23,929
      
24,486
  
Total Current Liab.
    
3,820
      
4,309
  
Total Other Liab.
    
-
      
-
  
Total Liabilities
    
3,820
      
4,309
  
Stockholders' Equity
    
20,109
      
20,177
  
Total Liabilities & Stockholders' Equity
  
$
23,929
    
$
24,486
  
 
                

Selected Comparative Historical Financial Data:
    
   
   
   
   
   
   
   
 
   
For the Quarter Ended
    
For the Nine Months ended
    
For the Years Ended
  
$
(000s
)
    
Q3'14
      
Q3'13
      
Q3'14
      
Q3'13
      
2013
      
2012
      
2011
      
2010
  
Total Revenues
    
$
7,314
    
$
9,618
    
$
20,550
    
$
21,689
    
$
29,550
    
$
25,611
    
$
19,388
    
$
16,705
  
Cost of sales
      
4,664
      
5,561
      
12,644
      
12,658
      
17,249
      
14,821
      
9,998
      
8,604
  
Gross Profit
      
2,650
      
4,056
      
7,906
      
9,031
      
12,301
      
10,790
      
9,390
      
8,101
  
Gross Profit %
      
36.2
%
    
42.2
%
    
38.5
%
    
41.6
%
    
41.6
%
    
42.1
%
    
48.4
%
    
48.5
%
R&D Expense
      
972
      
1,602
      
3,439
      
4,148
      
5,834
      
4,486
      
4,878
      
2,586
  
SG&A Expense
      
1,940
      
1,380
      
5,345
      
3,702
      
5,461
      
4,852
      
3,424
      
2,941
  
Operating Income (Loss)
      
(262
)
    
1,074
      
(878
)
    
1,181
      
1,006
      
1,452
      
1,088
      
2,574
  
Other Inc. (Expense)
      
1
      
2
      
(1
)
    
11
      
13
      
(1
)
    
(12
)
    
(15
)
Net Income (Loss)
      
(261
)
    
1,076
      
(879
)
    
1,192
      
1,019
      
1,451
      
1,076
    
$
2,559
  
Inc Tax (Ben.) Prov.
      
9
      
359
      
(238
)
    
399
      
487
      
509
      
(5,133
)
    
-
  
Net Income (Loss)
    
$
(270
)
  
$
717
    
$
(641
)
  
$
793
    
$
532
    
$
942
    
$
6,209
      
2,559
  
Net Income (Loss) - per Share
      
(0.03
)
    
0.08
      
(0.07
)
    
0.09
    
$
0.06
    
$
0.11
    
$
0.73
      
0.29
  
Wt. Avg. No. Shares (Millions)
      
9.611
      
9.235
      
9.503
      
8.887
      
9.520
      
8.615
      
8.556
      
8.865
  
Working capital
    
$
13,180
    
$
14,072
    
$
13,180
    
$
14,072
    
$
14,221
    
$
7,630
    
$
6,134
    
$
4,560
  
Total assets
      
23,929
      
24,326
      
23,929
      
24,326
      
24,487
      
17,335
      
15,486
      
9,086
  
Total liabilities
      
3,819
      
3,935
      
3,819
      
3,935
      
4,310
      
3,460
      
2,991
      
3,277
  
Equity
      
20,109
      
20,391
      
20,109
      
20,391
      
20,177
      
13,875
      
12,495
      
5,809
  





 Chembio Diagnostics, Inc.
Investor Relations
 Company Contact
 3661 Horseblock Road
Vida Strategic Partners
Susan Norcott
 Medford, NY 11763
Stephanie C. Diaz
 631-924-1135 x125
 Ph. 631-924-1135
(415) 675-7401
 snorcott@chembio.com
 Fax 631-924-2065
sdiaz@vidasp.com
 
 www.chembio.com
 
 


PAGE 2 – See Graphics

DPP® Technology
Competitive Advantages For POC Testing

• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results


Senior Management Team
John J. Sperzel, President & CEO: 25+ years of leadership in the POC Diagnostics market
Richard J. Larkin, CFO: 25+ years of leadership in Finance and Administration
Sharon Klugewicz, COO: 20+ years of leadership in Operations, Marketing, QA/RA
Javan Esfandiari, CSTO: 15+ years developing POC IVD tests and inventor of DPP® technology
Michael Steele, VP Sales/Marketing/BD: 20+ years of commercial operations and BD IVD market
Tom Ippolito, VP RA: 20+ years of Quality and Regulatory Affairs leadership in IVD and Pharma

Independent Directors
Katherine L. Davis (Chairman) - Former Lieutenant Governor for the State of Indiana
Barbara DeBuono, MD, MPH: former NY Commissioner of Health and RI Director of Health
Peter Kissinger, Ph.D.: founder of numerous biotechnology / biomedical companies
Gary Meller, MD, MBA: broad experience in medical and information technology


Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostics, Inc.'s most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –November 2014